Rezolute (NASDAQ:RZLT) Stock Price Target Raised at Wedbush

Rezolute (NASDAQ:RZLT – Get Free Report) had its price target boosted by equities research analysts at Wedbush from $6.00 to $10.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush‘s target price would indicate a potential upside of 179.33% from the company’s current price.

Several other equities analysts have also recently issued reports on RZLT. Citizens Jmp upped their price objective on Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, October 6th. HSBC upgraded Rezolute to a “buy” rating in a research note on Friday, September 25th. Zacks Research lowered Rezolute from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Lake Street Capital boosted their price target on Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, October 6th. Finally, Citigroup restated a “market outperform” rating on shares of Rezolute in a research note on Thursday, October 15th. Twelve investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.67.

Read Our Latest Stock Report on RZLT

Rezolute Stock Down 1.9%

Shares of Rezolute stock opened at $3.58 on Tuesday. Rezolute has a 52-week low of $1.07 and a 52-week high of $11.16. The company has a 50-day simple moving average of $4.05 and a two-hundred day simple moving average of $3.93.

Rezolute (NASDAQ:RZLT – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.01. As a group, analysts anticipate that Rezolute will post -0.66 earnings per share for the current fiscal year.

Institutional Trading of Rezolute

A number of large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its stake in Rezolute by 273.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 530,229 shares of the company’s stock valued at $1,617,000 after buying an additional 388,346 shares during the last quarter. Siren L.L.C. bought a new position in shares of Rezolute during the 1st quarter valued at $10,151,000. Jennison Associates LLC purchased a new position in shares of Rezolute in the 1st quarter worth $10,489,000. Bank of New York Mellon Corp purchased a new position in shares of Rezolute in the 2nd quarter worth $1,104,000. Finally, Wellington Management Group LLP bought a new stake in shares of Rezolute in the second quarter worth $276,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Company Profile

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.